BioSpace News Archive

Flow directed catheters are designed so that the flow of blood through an artery directs the catheter tip along the arterial flow path and to the target site.

Ventyx Biosciences, Inc. announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief Medical Officer, as well as the closing of a $51.0 million Series B convertible preferred stock financing round.

Aerie Pharmaceuticals, Inc. announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie’s Vice President of Research and Discovery.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria.

Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monday, September 27th, 2021 at 1:20 p.m. ET.

BioCryst Pharmaceuticals, Inc. announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration Oncology Center of Excellence, Amy McKee, M.D., to its board of directors.

PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide therapeutic platform at two scientific conferences in September.

Zynerba Pharmaceuticals, Inc. announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced it will present multiple posters and presentations on losmapimod for facioscapulohumeral muscular dystrophy during the Virtual Congress of the World Muscle Society.

GT Biopharma, Inc., a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer cell engager, TriKE platform, announced Dr. Jeffrey Miller’s mini-oral presentation at the European Society for Medical Oncology Congress 2021.